Sandy Cove Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Sandy Cove Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10	Closed	–	–	153
2022 Q1	$0	Hold	10	–	–	﹤0.01%	417
2021 Q4	$1K	Buy	+10	New	+$1K	﹤0.01%	367

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sandy Cove Advisors's DNTH Position: Q2 2022 in Review

Sandy Cove Advisors sold out of Dianthus Therapeutics (DNTH) in Q2 2022, closing a stake of 10 shares.

Sandy Cove Advisors first reported a position in DNTH in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 75 funds tracked by Wall St. Rank hold DNTH as of Q2 2022.

Sandy Cove Advisors reported no remaining Dianthus Therapeutics position as of Q2 2022 after selling out during the quarter.
Sandy Cove Advisors sold 10 Dianthus Therapeutics shares in Q2 2022.
Sandy Cove Advisors first reported a position in Dianthus Therapeutics in Q4 2021 and held it in 2 quarters.
Sandy Cove Advisors's Dianthus Therapeutics position peaked at $1K in Q4 2021.
75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2022.

Based on Sandy Cove Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.